公开(公告)号：US20240263239A1

公开(公告)日：2024-08-08

申请号：US18036392

申请日：2021-11-10

Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services

Inventor： Keji Zhao

IPC: C12Q1/6886 ,  C12N9/12 ,  C12Q1/6806 ,  C12Q1/6841

CPC classification number: C12Q1/6886 ,  C12N9/1264 ,  C12Q1/6806 ,  C12Q1/6841 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158

Abstract: Compositions and methods for determining and identifying both chromatin occupancy and transcriptome simultaneously in the same single cell.

公开(公告)号：US20240254545A1

公开(公告)日：2024-08-01

申请号：US18559322

申请日：2022-05-06

Applicant: The Broad Institute, Inc. ,  Massachusetts Institute of Technology

Inventor： Xiao Wang ,  Jingyi Ren ,  Hu Zeng

IPC: C12Q1/6841 ,  C12N15/10 ,  C12Q1/6876 ,  G01N21/64

CPC classification number: C12Q1/6841 ,  C12N15/1093 ,  C12Q1/6876 ,  G01N21/6458 ,  G01N21/6486 ,  C12Q2600/118 ,  C12Q2600/136

Abstract: The present disclosure provides methods for profiling spatiotemporal gene expression, including methods for profiling spatiotemporal gene expression in vivo in a subject. The present disclosure also provides methods for profiling the role of post-transcriptional modification in spatiotemporal gene expression, methods for studying the role of spatiotemporal gene expression in the development or progression of a disease or disorder, methods for screening for an agent capable of modulating spatiotemporal gene expression, methods for diagnosing a disease or disorder in a subject, and methods for treating a disease or disorder in a subject. Oligonucleotide probes useful in the methods described herein are also provided by the present disclosure. The present disclosure also provide kits comprising the oligonucleotide probes disclosed herein. Systems for profiling spatiotemporal gene expression are also provided by the present disclosure.

公开(公告)号：US20240247312A1

公开(公告)日：2024-07-25

申请号：US18014801

申请日：2021-07-05

Applicant: BIOMÉRIEUX ,  BIOASTER

Inventor： Laurence VACHOT ,  François MALLET ,  Guillaume MONNERET ,  Virginie MOUCADEL ,  Alexandre PACHOT ,  Estelle PERONNET ,  Thomas RIMMELÉ ,  Julien TEXTORIS ,  Fabienne VENET

IPC: C12Q1/6883 ,  C12Q1/6851

CPC classification number: C12Q1/6883 ,  C12Q1/6851 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: An in vitro or ex vivo method for determining the risk of incidence of a healthcare-associated infection in a patient, including a step of measuring the expression of at least one gene encoding a pro-inflammatory cytokine receptor located on chromosome 2 in the region 2q11-2q12, in a biological sample from the patient.

公开(公告)号：US12043870B2

公开(公告)日：2024-07-23

申请号：US16753039

申请日：2018-10-02

Applicant: The Broad Institute, Inc. ,  Massachusetts Institute of Technology ,  Dana-Farber Cancer Institute, Inc.

Inventor： Aviv Regev ,  Orit Rozenblatt-Rosen ,  Benjamin Izar ,  Livnat Jerby ,  Asaf Rotem

IPC: C12Q1/6886 ,  A61K31/506 ,  A61K39/395

CPC classification number: C12Q1/6886 ,  A61K31/506 ,  A61K39/3955 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The subject matter disclosed herein is generally directed to detecting and modulating novel gene signatures for the treatment and prognosis of cancer. The novel gene signatures predict overall survival in cancer and can be targeted therapeutically. Specifically, disclosed is a resistance program identified by a comprehensive single-cell profiling study in melanoma patients, which was validated in two large validation cohorts. Using a large-scale in silico prediction, CDK4/6 inhibitors were identified as a class of drugs that may reverse this resistance program. These predictions were validated in melanoma cell lines, patient-derived co-culture models, and melanoma in vivo models, which show that the combination of abemaciclib and immune checkpoint blockade (ICB) overcome intrinsic drug resistance. The present invention provides for detecting an immunotherapy resistance signature and modulating the signature with CDK4/6 inhibition. Also provided is a novel phased immunotherapy and CDK4/6 inhibitor combination therapy regimen.

公开(公告)号：US20240238384A1

公开(公告)日：2024-07-18

申请号：US18413204

申请日：2024-01-16

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Sahar Gelfman ,  Arden Moscati ,  Aris Baras ,  Eli A. Stahl ,  Giovanni Coppola ,  Ann Ligocki ,  Carmelo Romano ,  Santiago Mendez Huergo ,  Jonathan Weyne ,  Tave Van Zyl ,  Rujin Wang ,  Charles Miller

IPC: A61K38/45 ,  A61K38/44 ,  C12Q1/6883

CPC classification number: A61K38/45 ,  A61K38/44 ,  C12Q1/6883 ,  C12Y113/11052 ,  C12Y207/01151 ,  C12Q2600/118

Abstract: Methods of treating B27-negative subjects having uveitis with an Inositol Polyphosphate Multikinase (IPMK) therapeutic agent and/or an Indoleamine 2,3-dioxygenase 2 (IDO2) agonist, and methods of identifying subjects having an increased risk of developing uveitis are described herein.

公开(公告)号：US20240229153A9

公开(公告)日：2024-07-11

申请号：US18497332

申请日：2023-10-30

Applicant: Nanomed Diagnostics B.V.

Inventor： Willem Frederik Rurup ,  Loes Irene Segerink ,  Roderik Adriaan Kraaijenhagen ,  Herbert Michael Pinedo ,  Albert Van Den Berg ,  Renske Daniela Maria Steenbergen ,  Jacobus Adrianus Nieuwenhuijzen ,  Idris Bahce ,  Geert Kazemier

IPC: C12Q1/6886 ,  C12Q1/6806 ,  C12Q1/686

CPC classification number: C12Q1/6886 ,  C12Q1/6806 ,  C12Q1/686 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Q2600/16

Abstract: The invention provides in vitro methods of determining whether an individual has a pre-cancer or cancer comprising determining the presence or absence of one or more methylation markers of a methylation marker set in a urine sample of said individual; and determining whether the individual has pre-cancer or cancer based on the detection of the presence or absence of said one or more methylation markers in the urine sample, wherein the presence of said one or more methylation markers indicates that the individual has pre-cancer or cancer. The invention further provides methods for typing pre-cancer or cancer based on the presence or absence of one or more methylation markers of a methylation marker set in a urine sample.

公开(公告)号：US20240218450A1

公开(公告)日：2024-07-04

申请号：US18338974

申请日：2023-06-21

Applicant: Board of Regents, The University of Texas System ,  Yale University

Inventor： William fraser SYMMANS ,  Bruno SINN ,  Christos HATZIS ,  Chunxiao FU ,  Rosanna LAU

IPC: C12Q1/6886 ,  A61K31/138 ,  A61K31/4196 ,  A61K31/566 ,  A61K45/06 ,  A61P35/04 ,  G16B10/00 ,  G16B25/10 ,  G16B25/20

CPC classification number: C12Q1/6886 ,  A61K31/138 ,  A61K31/4196 ,  A61K31/566 ,  A61K45/06 ,  A61P35/04 ,  G16B10/00 ,  G16B25/10 ,  G16B25/20 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: Provided herein are methods of determining tumoral sensitivity to hormonal (endocrine) therapy based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER/PR index), and may have additional consideration for the proportion of ER gene (ESR1) RNA transcripts that contain a mutation relative to the value of the SETER/PR index. Further provided are methods of treating breast cancer patients determined to be sensitive to an endocrine therapy by the SETER/PR index.

公开(公告)号：US12018334B2

公开(公告)日：2024-06-25

申请号：US17411606

申请日：2021-08-25

Applicant: Exosome Diagnostics, Inc.

Inventor： Mikkel Noerholm ,  Susan Belzer ,  Charlotte Romain ,  Johan Karl Olov Skog ,  Leileata M. Russo ,  Wayne Comper

IPC: C12P19/34 ,  C12N7/00 ,  C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12N7/00 ,  C12N2795/18122 ,  C12N2795/18131 ,  C12Q2600/106 ,  C12Q2600/118

Abstract: The present invention features a method and kit for isolating microvesicles or extracting microvesicle nucleic acids from a biological sample by using a control particle. The present invention provides control particles that are viruses or virus-like particles, such as bacteriophages, that contain control nucleic acids that can be detected to assess the accuracy, reliability, and efficiency of the microvesicle isolation or nucleic acid extraction steps. The methods described herein may further comprise the analysis of the presence, absence, or level of at least one biomarker associated with a disease or medical condition for diagnosing, prognosing, or monitoring the disease or medical condition.

公开(公告)号：US20240200125A1

公开(公告)日：2024-06-20

申请号：US18542193

申请日：2023-12-15

Applicant: Droplet Biosciences, Inc.

Inventor： Wendy Winckler Adamovich

IPC: C12Q1/6851 ,  C12Q1/6876 ,  G01N33/68

CPC classification number: C12Q1/6851 ,  C12Q1/6876 ,  G01N33/6893 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2800/26

Abstract: The invention provides methods of detecting, or predicting the aggressiveness of, a tumor by measuring cancer biomarkers in surgical drain fluid that may be collected from the site of a surgery such as a tumor resection or lymphadenectomy. Surgical drain fluid (SDF), and the lymph component of SDF in particular, contains biomarkers that demonstrably correlate to future cancer outcomes and that are thus predictive of the growth or aggressiveness of a tumor as well as surgical site infection and/or sepsis.

公开(公告)号：US20240182979A1

公开(公告)日：2024-06-06

申请号：US18442036

申请日：2024-02-14

Applicant: Myriad Genetics, Inc.

Inventor： Steven Stone ,  Alexander Gutin ,  Susanne Wagner ,  Julia Reid

IPC: C12Q1/6886 ,  G16B20/00 ,  G16B20/10 ,  G16B20/20 ,  G16B40/00 ,  G16B40/30

CPC classification number: C12Q1/6886 ,  G16B20/00 ,  G16B20/10 ,  G16B20/20 ,  G16B40/30 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G16B40/00

Abstract: Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.